Low CSF Concentrations of Cyclic GMP in Schizophrenia

1983 ◽  
Vol 142 (3) ◽  
pp. 288-291 ◽  
Author(s):  
W. F. Gattaz ◽  
H. Cramer ◽  
H. Beckmann
Keyword(s):  
Cerebrospinal Fluid ◽  
Cyclic Gmp ◽  
Homovanillic Acid ◽  
Healthy Controls ◽  
Neuroleptic Treatment ◽  
Cholinergic Activity ◽  
Schizophrenic Patients ◽  
Csf Levels

SummaryIncreasing evidence suggests that the concentrations of cyclic guanosine 3′5′-monophosphate (cGMP) in the cerebrospinal fluid (CSF) may reflect central cholinergic activity. When the concentrations of this nucleotide in the CSF from 28 schizophrenic patients (13 without and 15 with neuroleptic treatment) and 16 psychiatrically healthy controls was determined the schizophrenics showed significantly lower CSF levels of cGMP as compared to controls.As dopamine and homovanillic acid concentrations were not altered in these CSF samples, this finding of reduced cGMP suggests a cholinergic-dopaminergic imbalance in schizophrenia, with a reduction of the former and consequently a relative dominance of the latter.

Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients

1997 ◽  
Vol 12 (6) ◽  
pp. 294-299 ◽  
Author(s):  
N Müller ◽  
P Dobmeier ◽  
M Empl ◽  
M Riedel ◽  
M Schwarz ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Interleukin 6 ◽  
Serum Levels ◽  
Healthy Controls ◽  
Central Action ◽  
Neuroleptic Treatment ◽  
Interleukin 6 Receptor ◽  
Schizophrenic Patients ◽  
Csf Levels ◽  
Paranoid Schizophrenic

SummarySoluble Interleukin-6 receptor (sIL-6R) levels are strongly related to the levels of Interleukin-6 (IL-6), and sIL-6Rs increase the immune activating properties of IL-6. We estimated sIL-6R serum levels in 25 schizophrenic patients and 25 healthy controls. In the patients, SIL-6R-CSF levels were also measured. The psychopathology was rated according to the AMDP system. We found a significant correlation between serum and cerebrospinal fluid (CSF) levels of sIL-6R, suggesting that serum levels may be a meaningful marker for the central action of sIL-6R. Moreover, significant correlations between the paranoid-hallucinatory syndrome and sIL-6R levels both in serum and CSF were observed. This finding suggests that IL-6 plays a role in the paranoid-hallucinatory symptomatology in schizophrenia. This can be understood regarding the influence of IL-6 to the catecholaminergic neurotransmission. The downregulating effects of neuroleptic treatment to sIL-6R demonstrate that the sIL-6R levels are decreased in the whole group of schizophrenic patients compared to controls.

Cerebrospinal Fluid Levels of 14-3-3 Gamma: What Does It Tell Us About Sporadic Creutzfeldt-Jakob Disease?

Pharmacology ◽  
2017 ◽  
Vol 100 (5-6) ◽  
pp. 243-245 ◽  
Author(s):  
Christian Humpel ◽  
Thomas Benke
Keyword(s):  
Cerebrospinal Fluid ◽  
High Risk ◽  
Retrospective Analysis ◽  
Short Report ◽  
Healthy Controls ◽  
Jakob Disease ◽  
Csf Levels ◽  
Fluid Levels ◽  
Very High ◽  
Probable Diagnosis

Clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by the analysis of Tau and 14-3-3 in the cerebrospinal fluid (CSF). In this short report, we report about a retrospective analysis performed on 2,296 routinely collected CSF samples, and 44 samples with a ratio of phosphoTau181/Tau <0.075 were selected. Analysis was performed with a novel 14-3-3 gamma CircuLex Elisa. We show that control levels were around 6,000 AU/mL and samples from Alzheimer patients were not different from those collected from healthy controls. Four cases of verified CJD had 14-3-3 CSF levels of >100,000 AU/mL, while 10 out of 12 suspected CJD samples with 14-3-3 CSF levels between 50,000-100,000 AU/mL were CJD positive. All samples with 14-3-3 levels between 15,000 and 50,000 AU/mL were not CJD cases but disorders with complex neuropathology. In conclusion, our data suggests that in CSF samples with a phospho-Tau-181/Tau ratio <0.075 CSF levels of 14-3-3 should be analyzed. Our data suggests a very high risk for CJD with 14-3-3 levels above 100,000 AU/mL and a probable diagnosis of CJD based on laboratory parameters above 50,000 AU/mL.

The effect of chlorpromazine on homovanillic acid levels in cerebrospinal fluid of schizophrenic patients

1974 ◽  
Vol 35 (4) ◽  
pp. 287-294 ◽  
Author(s):  
Bengt Fyr� ◽  
Birgitta Wode-Helgodt ◽  
Stefan Borg ◽  
G�ran Sedvall
Keyword(s):  
Cerebrospinal Fluid ◽  
Homovanillic Acid ◽  
Schizophrenic Patients

Cerebrospinal Fluid Analyses in Migraine Patients and Controls

Cephalalgia ◽  
1995 ◽  
Vol 15 (6) ◽  
pp. 489-493 ◽  
Author(s):  
JF Rothrock ◽  
KR Mar ◽  
TL Yaksh ◽  
A Golbeck ◽  
AC Moore
Keyword(s):  
Amino Acids ◽  
Cerebrospinal Fluid ◽  
Homovanillic Acid ◽  
Divalproex Sodium ◽  
Transformed Migraine ◽  
Hydroxyindoleacetic Acid ◽  
Csf Levels ◽  
Baseline Values ◽  
Central Neurotransmitters

To investigate the role of central neurotransmitters in the pathogenesis of migraine, we measured cerebrospinal fluid (CSF) levels of certain amino acids (glycine, taurine, glutamine) and metabolites of biogenic amines (5-hydroxyindoleacetic acid and homovanillic acid) in 38 migraine patients and compared them with the levels from 10 headache-free controls. The levels of taurine, glycine and glutamine were significantly higher in the migraine patients (p < 0.0001 for taurine and glycine; p < 0.0009 for glutamine); there were no significant differences among the three migraine subgroups (infrequent migraine, frequent migraine and transformed migraine). In seven patients subsequently treated with divalproex sodium, CSF taurine levels decreased significantly from pretreatment baseline values. These data support the concept that migraine is at least in part a disorder of central neurotransmission.

scholarly journals Imbalanced Kynurenine Pathway in Schizophrenia

2014 ◽  
Vol 7 ◽  
pp. IJTR.S16800 ◽  
Author(s):  
Magdalena E. Kegel ◽  
Maria Bhat ◽  
Elisabeth Skogh ◽  
Martin Samuelsson ◽  
Kristina Lundberg ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Cerebrospinal Fluid ◽  
Liquid Chromatography ◽  
Quinolinic Acid ◽  
Kynurenic Acid ◽  
Kynurenine Pathway ◽  
The Other ◽  
Healthy Controls ◽  
Liquid Chromatography Mass Spectrometry ◽  
Csf Levels

Several studies suggest a role for kynurenic acid (KYNA) in the pathophysiology of schizophrenia. It has been proposed that increased brain KYNA levels in schizophrenia result from a pathological shift in the kynurenine pathway toward enhanced KYNA formation, away from the other branch of the pathway leading to quinolinic acid (QUIN). Here we investigate the levels of QUIN in cerebrospinal fluid (CSF) of patients with schizophrenia and healthy controls, and relate those to CSF levels of KYNA and other kynurenine metabolites from the same individuals. CSF QUIN levels from stable outpatients treated with olanzapine (n = 22) and those of controls (n = 26) were analyzed using liquid chromatography-mass spectrometry. No difference in CSF QUIN levels between patients and controls was observed (20.6 ± 1.5 nM vs. 18.2 ± 1.1 nM, P = 0.36). CSF QUIN was positively correlated to CSF kynurenine and CSF KYNA in patients but not in controls. The CSF QUIN/KYNA ratio was lower in patients than in controls ( P = 0.027). In summary, the present study offers support for an over-activated and imbalanced kynurenine pathway, favoring the production of KYNA over QUIN in patients with schizophrenia.

Melatonin immunoreactivity in cerebrospinal fluid of schizophrenic patients and healthy controls

1984 ◽  
Vol 11 (2) ◽  
pp. 107-110 ◽  
Author(s):  
Helmut Beckmann ◽  
Lennart Wetterberg ◽  
Wagner F. Gattaz
Keyword(s):  
Cerebrospinal Fluid ◽  
Healthy Controls ◽  
Schizophrenic Patients
Sign in / Sign up

Export Citation Format

Share Document